Patents by Inventor Udo Lange

Udo Lange has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,2,3,4-SUBSTITUTED QUINOLINE COMPOUNDS AS SIP MODULATORS
    Publication number: 20210147381
    Abstract: The invention relates to 1,2,3,4-substituted quinoline compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: July 16, 2018
    Publication date: May 20, 2021
    Inventors: Wilhelm AMBERG, Hervé GENESTE, Wilfried HORNBERGER, Udo LANGE, Mario MEZLER, Michael OCHSE, Frank OELLIEN, Sean C. TURNER, Jeroen VAN BERGEIJK, Elizabeth VAN DER KAM
  • SPIRO-COMPOUNDS AS SIP MODULATORS
    Publication number: 20200055817
    Abstract: The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Inventors: Wilhelm AMBERG, Jeroen VAN BERGEIJK, Herve GENESTE, Wilfried HORNBERGER, Elizabeth Louise VAN DER KAM, Udo LANGE, Mario MEZLER, Michael OCHSE, Frank OELLIEN, Patrick WALLESER, Sean C. TURNER
  • Fused heterocyclic compounds as S1P modulators
    Patent number: 10556907
    Abstract: The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: February 11, 2020
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Udo Lange, Michael Ochse, Elizabeth van der Kam, Jeroen van Bergeijk, Sean Turner, Frank Oellien, Patrick Walleser, Wilhelm Amberg, Wilfried Hornberger, Herve Geneste, Mario Mezler, Charles Hutchins
  • Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
    Publication number: 20190290645
    Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: February 14, 2019
    Publication date: September 26, 2019
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
    Publication number: 20190290632
    Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: February 14, 2019
    Publication date: September 26, 2019
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • Fused (hetero)cyclic compounds as S1P modulators
    Patent number: 10280159
    Abstract: The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: May 7, 2019
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilhelm Amberg, Udo Lange, Herve Geneste, Michael Ochse, Ralf Biesinger, Frank Oellien
  • Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
    Publication number: 20170172993
    Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS
    Publication number: 20170174672
    Abstract: The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 22, 2017
    Inventors: Wilhelm Amberg, Udo Lange, Herve Geneste, Michael Ochse, Ralf Biesinger, Frank Oellien
  • Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
    Publication number: 20170173009
    Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
    Patent number: 9656955
    Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 23, 2017
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying X. Wang, Hongyu H. Zhao, Huan-Qiu Li, Jason T. Brewer, Irini Zanze, Justin Dietrich, Anil Vasudevan, Stevan W. Djuric, Yanbin Lao, Charles W. Hutchins
  • Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
    Patent number: 9650334
    Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 16, 2017
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying X. Wang, Hongyu H. Zhao, Huan-Qiu Li, Jason T. Brewer, Irini Zanze, Justin Dietrich, Anil Vasudevan, Stevan W. Djuric, Yanbin Lao, Charles W. Hutchins
  • Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
    Patent number: 9586942
    Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: March 7, 2017
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
    Patent number: 9586945
    Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: March 7, 2017
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS
    Publication number: 20170057966
    Abstract: The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: August 26, 2016
    Publication date: March 2, 2017
    Inventors: Udo Lange, Michael Ochse, Elizabeth van der Kam, Jeroen van Bergeijk, Sean Turner, Frank Oellien, Patrick Walleser, Wilhelm Amberg, Wilfried Hornberger, Herve Geneste, Mario Mezler, Charles Hutchins
  • GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
    Publication number: 20170037016
    Abstract: The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 9, 2017
    Inventors: Astrid Netz, Wilhelm Amberg, Udo Lange, Michael Ochse, Charles W. Hutchins, Francisco-Xavier Garcia-Ladona, Wolfgang Wernet, Andreas Kling
  • 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
    Patent number: 9550754
    Abstract: The present invention relates to 4,5-dihydropyrazole derivatives of the formula (I) and physiologically tolerated salts thereof which are GlyT1 inhibitors. The invention further relates to pharmaceutical compositions comprising such 4,5-dihydropyrazole derivatives, and the use of such 4,5-dihydropyrazole derivatives for therapeutic purposes.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: January 24, 2017
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Wilhelm Amberg, Jason Brewer, Charles Hutchins, Udo Lange, Yanbin Lao, Huan-Qiu Li, Frauke Pohlki, Anil Vasudevan, Ying Wang, Hongyu Zhao
  • Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors
    Patent number: 9475782
    Abstract: The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: October 25, 2016
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Astrid Netz, Wilhelm Amberg, Udo Lange, Michael Ochse, Charles W. Hutchins, Francisco-Xavier Garcia-Ladona, Wolfgang Wernet, Andreas Kling
  • Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
    Patent number: 9365512
    Abstract: The present invention relates to isoindoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such isoindoline derivatives, and the use of such isoindoline derivatives for therapeutic purposes.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: June 14, 2016
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Wilhelm Amberg, Udo Lange, Michael Ochse, Frauke Pohlki, Charles W. Hutchins, Irini Zanze, Hongyu H. Zhao, Huan-Qiu Li, Ying X. Wang
  • Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
    Patent number: 9309200
    Abstract: The present invention relates to benzazepine derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such benzazepine derivatives, and the use of such benzazepine derivatives for therapeutic purposes.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: April 12, 2016
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Wilhelm Amberg, Udo Lange, Michael Ochse, Frauke Pohlki, Berthold Behl, Mario Mezler, Wilfried Hornberger, Charles W. Hutchins
  • Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT-receptors
    Patent number: 9296697
    Abstract: The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for treating and/or for the prophylaxis of illnesses which are modulated by a 5-HT5-receptor activity, in particular, for treating and/or for the prophylaxis of neurodegenerative and neuropsychiatric disorders, and signs, symptoms and dysfunctions associated with said disorders.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: March 29, 2016
    Assignees: Abbott Laboratories, AbbVie Deutschland GmbH & Co. KG
    Inventors: Wilhelm Amberg, Astrid Netz, Andreas Kling, Michael Ochse, Udo Lange, Charles W. Hutchins, Francisco Javier Garcia-Ladona, Wolfgang Wernet, Alfred Hahn